AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 251 min read$CODX

Co-Diagnostics, Inc. (CODX): Submission of Matters to a Vote of Security Holders

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously announced on September 4, 2026, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did n

Original reporting
SEC EDGAR 8-K
Published Sep 25, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CODX
Neutral
medium confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The filing provides the first public notice of governance challenges at Co‑Diagnostics, but no material financial impact is evident.

02

Market read

A niche governance filing with limited trading relevance; primarily of interest to existing shareholders and potential activists.

03

What to watch

Potential upcoming proxy contest or shareholder activism not yet disclosed.

Relevance 6/10Novelty 2/10Timing: adjourned meeting set for Sep 30, 2026

Background

SEC Form 8‑K filing (Item 5.07) reporting the inability to achieve quorum at two scheduled annual meetings and the subsequent adjournments.

Company-level read

Ticker impact

$CODXNeutralMedium confidence
Context

Co‑Diagnostics failed to achieve a quorum at its annual meetings on Sep 3 and Sep 24, causing the meetings to be adjourned to Sep 30, 2026.

Expected impact

Minimal short‑term price movement; potential slight downside if investors view governance weakness negatively.

Evidence & confidence

No immediate financial impact, but governance concerns could affect investor sentiment.

Market effects

Sector

Limited; governance issue is specific to Co‑Diagnostics and does not affect the broader diagnostics sector.

Regional

None

Global

None

Counterpoint

What could challenge this read

The quorum failure could be a catalyst for activist investors to push for board changes, potentially creating upside if a restructuring plan is announced.

Key entities

  • Company
    Co‑Diagnostics, Inc.

    Medical diagnostics company filing the 8‑K.

  • Executive
    Dwight Egan

    CEO of Co‑Diagnostics who signed the filing.

Read at source← All news

Related articles

OCT 27
$CODXMed

CoSara submits tuberculosis test for India regulatory review

Co-Diagnostics' India joint venture, CoSara, submitted its tuberculosis test for regulatory review in India, reporting 97.3% sensitivity and 96.0% specificity. The test, using Co-Diagnostics' technology, aims for approval by Q4 2026 to begin sales in India and South Asia. India has the highest tuberculosis burden globally, according to the WHO.

investing.com2 min
OCT 27
$CODXMedAI 8/10

Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Co-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.

prnewswire.com2 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min